Angiocrine Bioscience, Inc.
Transforming medicine through engineered cellular therapies that restore, regenerate, and repair tissues and organs.
Transforming medicine through engineered cellular therapies that restore, regenerate, and repair tissues and organs.
Angiocrine Bioscience, Inc. is a private, clinical stage engineered cell therapy company that aims to transform medicine through engineered cellular therapies that restore, regenerate, and repair tissues and organs. Founded in 2012 and headquartered in the United States, the company is focused on harnessing the power of genetically modified human endothelial cells to address serious medical conditions.
The company's proprietary engineered endothelial cell (E-CEL®) therapies have garnered attention for their potential to treat multiple life-threatening hemato-oncologic and immunologic conditions, as well as regenerate tissues and organs affected by diseases. At 19 December 2022, Angiocrine Bioscience secured a significant $15.00M grant investment from the California Institute for Regenerative Medicine.
Angiocrine Bioscience operates within the Biotechnology and Health Care industries, positioning itself at the forefront of innovative medical advancements. With a focus on cellular therapies, the company holds promise for disrupting traditional medical treatments and offering new possibilities for patients with serious medical conditions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $15.00M | 1 | California Institute for Regenerative Medicine | 19 Dec 2022 |
| Private Equity Round | $58.12M | - | 15 Oct 2021 | |
| Venture Round | $4.00M | 1 |
|
13 Mar 2013 |
No recent news or press coverage available for Angiocrine Bioscience, Inc..
We care about your data, and we'd love to use cookies make your experience better.
